Primary CNS lymphoma

Most primary CNS lymphomas are a form of diffuse large B-cell lymphoma. Their location makes treatment different from lymphoma primarily in lymph nodes. “Primary” distinguishes this diagnosis from systemic lymphoma that later spreads to the CNS.

Diagnosis usually requires tissue or other specialist testing, together with imaging and assessment for disease elsewhere. Eye examination and spinal-fluid evaluation are used when appropriate and safe.

The malignant lymphocytes develop acquired changes in growth and survival pathways. Immune deficiency is an important risk setting, including some people with HIV or immunosuppression, but primary CNS lymphoma also occurs without an identified immune disorder.

Epstein-Barr virus is associated particularly with immune-deficiency-related cases. It does not explain all disease in immunocompetent people. The lymphoma is not contagious.

Symptoms depend on the site and can include weakness, balance problems, headache, changes in thinking or behavior, seizures or visual disturbance. These symptoms have many possible causes and need neurological assessment.

The disease and its treatment can both affect cognitive and physical function. A response in the lymphoma does not mean every neurological symptom immediately resolves, so rehabilitation and symptom care may be needed.

High-dose methotrexate-based combinations are central because they can reach the CNS. Additional medicines and the regimen’s intensity depend on age, fitness and organ function. Treatment differs from ordinary R-CHOP-based systemic lymphoma care.

For eligible patients who respond, high-dose chemotherapy followed by autologous stem cell rescue is an established consolidation option. Carefully selected radiotherapy or other consolidation approaches may be used in different circumstances, with attention to delayed neurological toxicity.

At relapse, treatment depends on previous therapy, the length of response and fitness. Options may include further CNS-active therapy, autologous transplantation if appropriate, targeted agents, radiotherapy or clinical trials. CAR-T is being used in selected specialist settings; donor stem cell transplantation is not routine CNS lymphoma treatment.

Care often involves hematology, neurology, ophthalmology and rehabilitation services. Problems with memory, mobility or vision can affect consent discussions, transport and medicine management as well as work and family life.

Methotrexate-based treatment needs monitoring of kidney function, drug clearance and interactions. High-dose consolidation involves a period of low blood counts and infection risk, followed by continued neurological and lymphoma follow-up.

The usual transplant pathway is autologous: cells are collected from the patient and returned after high-dose chemotherapy to restore blood production. It does not require a marrow registry match.

Allogeneic transplantation is not a standard routine pathway for primary CNS lymphoma. A reader can still join a registry to support people whose diseases do require donated stem cells; that wider mission should remain distinct from this condition’s usual treatment.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?